U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT07535242) titled 'Serum GFAP, NfL, VEGF and Clinical Progression in Progressive MS' on April 03.
Brief Summary: This study aimed to investigate whether the biomarkers GFAP, NfL, and VEGF-recently considered important guides for better understanding the pathophysiology of MS-also serve as indicators of clinical progression in MS.
Study Start Date: April 21
Study Type: OBSERVATIONAL
Condition:
Multiple Sclerosis
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Ondokuz Mayıs University
Information provided by (Responsible Party): Seda Nur Kemer, Ondokuz Mayıs University
Published by HT Digital Content Services with permission from Heal...